GlobeNewswire

Z-Wave Alliance Brings Diverse Smart Home Ecosystem to International Integrators at ISE 2018

Dela

The Z-Wave Pavilion will feature the latest smart home devices for the pro channel from member companies along with the now available global Z-Wave toolkit for Z-Wave projects

 

AMSTERDAM, the Netherlands, Feb. 06, 2018 (GLOBE NEWSWIRE) -- ISE 2018 -- Stand 9-F170  -- The Z-Wave Alliance, a global membership organization dedicated to advancing the popular Z-Wave wireless smart home protocol, will host the Z-Wave Pavilion at ISE 2018. The Alliance is also demoing their award-winning installation toolkit to make installation and testing of a Z-Wave smart home mesh network even easier for the pro installer community.

The Z-Wave Pavilion will feature smart home products & services for integrators such as new smart door locks for residential and MDU applications, smart entertainment control, advanced IoT sensors and more at ISE 2018. Featured members in the Pavilion include:

  • Aeotec
  • ASSA ABLOY
  • eZLO
  • Fifthplay
  • Hogar Controls
  • LEEDARSON
  • Neeo
  • Oblo Living
  • UTC

"The smart home market is on the move in the UK and Europe and so are our European-based members; we've got a host of new products and solutions being shown off at ISE specifically for the integrator community," said Mitchell Klein, Z-Wave Alliance Executive Director. "Our Certified Installer Toolkit is now available to integrators around the globe and we were excited to take home several Best of awards at CEDIA this year. It truly is an invaluable tool for the installation community."

Z-Wave will also show off the award-winning Z-Wave Certified Installer Toolkit (CIT), available now for integrators around the world to assist in setting up and maintaining Z-Wave networks in their installation projects. The Z-Wave CIT is the only integrator diagnostics device to include global language support.

Integrators who purchase a toolkit at ISE 2018 will receive their first-year of Z-Wave Alliance membership for only one dollar. After purchase of a CIT, all software updates and upgrades will be available at no charge if the integrator remains a member in good standing. Additional toolkits will be available for purchase for all Alliance members. For more information on the CIT, visit the website.

For more information on the Z-Wave Alliance, please visit http://z-wavealliance.org. For updates from Z-Wave at ISE 2018,  follow the Z-Wave Alliance on FacebookTwitter and LinkedIn and with the #ISE2018 hashtag.

About Z-Wave
Z-Wave® technology is an open internationally recognized ITU standard (G.9959). It is the leading wireless home control technology in the market today, with over 2400 certified interoperable products worldwide.  Represented by the Z-Wave Alliance, and supported by more than 700 companies around the world, the standard is a key enabler of smart living solutions for home safety and security, energy, hospitality, office and light commercial applications.

Z-Wave® is a registered trademark of Sigma Designs (NASDAQ SIGM) and its subsidiaries in the United States and other countries.

About the Z-Wave Alliance
Formed in January 2005, the Z-Wave Alliance is a consortium of leading companies in the home technology space dedicated to solidifying Z-Wave as the standard for wireless home control products. The principal members include: ADT, Alarm.com, ASSA ABLOY, FIBARO, Huawei, Ingersoll Rand Nexia Intelligence, Jasco Products, Leedarson, LG Uplus, Nortek Security & Control, SmartThings and Sigma Designs.  Alliance members lead the home controls market, providing leading edge products and systems that deliver increased comfort, convenience, energy conservation, safety and security.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including statements about the benefits of Z-Wave Alliance membership, the benefits of the use of Z-Wave in product offerings, including the benefits of certain enhanced features of Z-Wave devices. Actual results may vary materially due to a number of factors including, but not limited to, consumer and customer acceptance of the Z-Wave Alliance (including its membership benefits), and Z-Wave technology in the relevant regions, the ability of the Z-Wave Alliance to compete with similar alliances in the industry and of the Z-Wave technology to compete with other technologies or related products in the market, if any, as well as other risks that are detailed from time to time in Z-Wave Alliance Members' reports to the Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward- looking statements, which speak only as of the date hereof. We undertake no obligation to publically release or otherwise disclose the result of any revision to these forward-looking statements that may be made as a result of events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

Press Contact:  
Caster Communications, Inc. at 401.792.7080
Ashley Daigneault ashley@castercomm.com (401) 651-3242
Alexandra Gil alex@castercomm.com (401) 792-7080

For digital images log on to www.castercomm.com




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Z-Wave Alliance via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Karolinska Development's portfolio company Modus Therapeutics has successfully dosed first cohort in phase 1 study of subcutaneously administered sevuparin22.2.2019 08:00:00Pressmeddelande

STOCKHOLM, February 22, 2019. Karolinska Development's portfolio company Modus Therapeutics announces today that the first cohort has been successfully dosed in its phase 1 study to explore the pharmacokinetics, safety and tolerability of subcutaneous sevuparin injections in healthy adults. Modus Therapeutic develops sevuparin for diseases with high unmet medical need with a focus on sickle cell disease (SCD) - a painful, inherited blood disorder affecting millions of people around the globe. Sevuparin has the potential to improve the SCD patients' blood flow reducing their pain and the amount of time they will need to spend in hospital. Intravenously administered sevuparin is currently being tested in a phase 2 study which completed enrollment in January 2019 and will report data in mid-2019. In order to broaden sevuparins potential to help SCD patients outside of the hospital setting, Modus Therapeutics in parallel explores subcutaneously administered sevuparin. The first cohort in a

Karolinska Development's portfolio company Modus Therapeutics has successfully dosed first cohort in phase 1 study of subcutaneously administered sevuparin22.2.2019 08:00:00Pressmeddelande

STOCKHOLM, February 22, 2019. Karolinska Development's portfolio company Modus Therapeutics announces today that the first cohort has been successfully dosed in its phase 1 study to explore the pharmacokinetics, safety and tolerability of subcutaneous sevuparin injections in healthy adults. Modus Therapeutic develops sevuparin for diseases with high unmet medical need with a focus on sickle cell disease (SCD) - a painful, inherited blood disorder affecting millions of people around the globe. Sevuparin has the potential to improve the SCD patients' blood flow reducing their pain and the amount of time they will need to spend in hospital. Intravenously administered sevuparin is currently being tested in a phase 2 study which completed enrollment in January 2019 and will report data in mid-2019. In order to broaden sevuparins potential to help SCD patients outside of the hospital setting, Modus Therapeutics in parallel explores subcutaneously administered sevuparin. The first cohort in a

Arcomas CFO lämnar bolaget21.2.2019 23:50:00Pressmeddelande

Arcomas CFO, AnnaPia Johansson har valt att avsluta sin tjänst för nya utmaningar utanför Arcoma. AnnaPia arbetar oförändrat vidare i sin nuvarande tjänst fram till augusti månad eller tills att en ersättare har rekryterats. "Jag vill tacka AnnaPia för hennes ambitiösa arbete för Arcoma och samtidigt önska henne lycka i framtida utmaningar " säger Jesper Söderqvist, VD Arcoma. Om Arcoma Arcoma, med lång erfarenhet av branschen, är en ledande leverantör av integrerade digitala röntgensystem med hög kvalitet och avancerad teknik. Arcomas produkter erbjuder den senaste digitala bildtekniken kombinerat med tekniskt avancerade rörliga positioneringssystem, vilket tillsammans med ergonomisk skandinavisk design, erbjuder kunden kompletta, konfigurerbara och funktionella digitala röntgensystem. Bolagets produkter säljs via återförsäljare samt via OEM-kunder och det finns idag över 3 500 av Arcomas röntgensystem installerade i hela världen. Arcoma är listat på Nasdaq First North. Certified Advi

Corline Biomedical AB offentliggör bokslutskommuniké för räkenskapsåret 201821.2.2019 08:45:00Pressmeddelande

Corline Biomedical AB ("Corline") publicerar härmed bokslutskommuniké för det fjärde kvartalet och räkenskapsåret 2018. Nedan följer en kort sammanfattning. Fullständig bokslutskommuniké finns tillgänglig på Corlines hemsida (www.corline.se) samt som bifogad fil. VD Henrik Nittmar kommenterar "2018 blev ett genombrottsår för Corline då bolaget gick från preklinisk till klinisk fas i utvecklingen av Renaparin® i och med att RENAPAIR 01-studien öppnade för rekrytering. Nu koncentrerar vi utvecklingsresurserna på att planera inför den värdehöjande fas 2- och fas 3-utvecklingen. Jämfört med branschkollegor har Corline en särskilt gynnsam position i och med att bolaget står på flera ben och parallellt arbetar mot lansering tillsammans med kunder inom medicinteknikområdet. Ett spännande 2019 stundar." Väsentliga händelser under det fjärde kvartalet 2018 Den vetenskapliga tidskriften Transplantation publicerar resultat från den prekliniska utvecklingen av Renaparin®. Här visas i stordjursmode

Arcoma AB: Investerarmöten våren 201915.2.2019 08:46:00Pressmeddelande

15 februari 2019 PRESSRELEASE Arcoma har som ambition att fortsätta öka sitt aktieägarfokus och kontinuerligt förbättra kommunikationen med aktieägare. Under våren 2019 kommer Arcoma medverka på flertalet investerarmöten där aktuella händelser och aktiviteter presenteras. Här ges en ökad inblick i bolagets vision och strategier samt en möjlighet till att ställa frågor till bolagets ledning. SvD Börsplus Temadag "Dubblare" Dag, tid och plats: 5 mars, kl. 13.00, GT 30, Grev Turegatan 30, Stockholm Stockholm Corporate Finance Life Science event Dag, tid och plats: 14 mars, kl. 07.30, Berns, Kammarsalen, Stockholm Redeyes Medtech & Diagnostics event Dag, tid och plats: 14:e maj, Redeye, Mäster Samuelsgatan 42, Stockholm För ytterligare information, vänligen kontakta: Arcomas VD Jesper Söderqvist, Telefon: +46 470 70 69 81, E-mail: jesper.soderqvist at arcoma.se Om Arcoma Arcoma, med lång erfarenhet av branschen, är en ledande leverantör av integrerade digitala röntgensystem med hög kvalite

Corline Biomedical AB: Första patient doserad med Renaparin®15.2.2019 08:42:00Pressmeddelande

Corline Biomedical AB ("Corline" eller "Bolaget") meddelar idag att man inkluderat första patienten i fas 1-studien RENAPAIR 01. Patienten inkluderades vid transplantationsavdelningen på Uppsala Akademiska sjukhus. Renaparin® är en produkt under utveckling för att förbättra njurtransplantation. I Corlines studie RENAPAIR 01 utvärderas produkten med avseende på tolerabilitet och säkerhet. Studien öppnades för patientrekrytering i slutet av 2018 och första patient är nu doserad och inkluderad i studien. Totalt skall 18 patienter rekryteras och när de 4 första patienterna är utvärderade i Uppsala, öppnas också Karolinska Universitetssjukhuset i Huddinge för rekrytering till studien. Henrik Nittmar, VD i Corline Biomedical AB, kommenterar "Det händer mycket i Corline för tillfället och alla arbetar hårt för att målbilden i bolaget skall uppfyllas. Det gäller såväl vår interna organisation som våra externa samarbetspartners. Därför är det extra roligt när vi når avgörande milstolpar i utvec

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum